Iwilfin (eflornithine tablets) — Medica

Initial criteria

• Patient has high-risk disease
• Medication is being used to reduce the risk of relapse
• Patient has had at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy

Approval duration

1 year